Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ANA598 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | Peginterferon and ribavirin + placebo BID for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks |
| 2 | EXPERIMENTAL | ANA598 200 mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks |
| 3 | EXPERIMENTAL | ANA598 400mg BID + Peginterferon and ribavirin for 12 weeks, followed by Peg-IFN and RBV for an additional 12 or 36 weeks |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | oral BID |
| ANA598 | DRUG | oral 200mg BID |
| Peginterferon | DRUG | 180 μg dose via subcutaneous injection weekly |
| Ribavirin | DRUG | oral 1000 mg/day for patients who weighed \< 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg |
Inclusion Criteria: * Male or female, ages 18 to 65 years * Documented chronic HCV infection, genotype 1a or 1b * Treatment-naïve Exclusion Criteria: * Female patients who are pregnant or breast-feeding * Infection with non-genotype 1 HCV * Previous treatment for HCV infection * HIV or HBV positi...
Top 20 of 28 competitors
ANA598 is an investigational small molecule being developed for the treatment of HCV infection, specifically genotype-1 chronic hepatitis C. It is intended to be used in combination with pegylated interferon and ribavirin, as evaluated in a Phase 2 clinical trial.
ANA598 is a small molecule antiviral agent. The specific molecular target is not disclosed in the available information. It is being studied for its antiviral activity against genotype-1 chronic HCV infection when administered with pegylated interferon and ribavirin.
ANA598 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational drug for the treatment of HCV infection.
ANA598 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug, not yet approved by regulatory authorities. The completed trial evaluated its safety, tolerability, and antiviral activity in combination with standard therapy.
ANA598 has one completed clinical trial, registered as NCT00978497. This Phase 2 study assessed the safety, tolerability, and antiviral activity of ANA598 in combination with pegylated interferon and ribavirin for genotype-1 chronic HCV infection. The trial enrolled 97 participants in the United States and Puerto Rico.
ANA598 is not known to have alternative names. It is an investigational small molecule developed by Roche Holding AG for the treatment of HCV infection, and it is distinct from other antiviral agents in its class.